Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Cidara Therapeutics (CDTX) over the last 4 years, with Sep 2025 value amounting to $15.1 million.

  • Cidara Therapeutics' Other Accumulated Expenses fell 42.66% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 42.66%. This contributed to the annual value of $26.0 million for FY2024, which is 44.37% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Other Accumulated Expenses stood at $15.1 million, which was up 0.92% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Other Accumulated Expenses ranged from a high of $26.3 million in Q3 2024 and a low of $7.9 million during Q1 2022.
  • For the 3-year period, Cidara Therapeutics' Other Accumulated Expenses averaged around $18.9 million, with its median value being $18.0 million (2023).
  • Per our database at Business Quant, Cidara Therapeutics' Other Accumulated Expenses soared by 94.20% in 2024 and then slumped by 42.74% in 2025.
  • Quarterly analysis of 4 years shows Cidara Therapeutics' Other Accumulated Expenses stood at $11.5 million in 2022, then surged by 56.41% to $18.0 million in 2023, then skyrocketed by 44.37% to $26.0 million in 2024, then slumped by 42.66% to $15.1 million in 2025.
  • Its Other Accumulated Expenses stands at $15.1 million for Q3 2025, versus $14.9 million for Q2 2025 and $20.7 million for Q1 2025.